An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes
- PMID: 21041563
- DOI: 10.1164/rccm.2009-038ST
An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes
Abstract
Rationale: Insurance coverage is an important determinant of access to care and is one potential cause of disparities in lung cancer care outcomes.
Objectives: We performed a systematic review of the available literature to examine the association between insurance status and lung cancer practices and outcomes.
Methods: We searched multiple electronic databases through November 6, 2008 for studies that examined the association between lung cancer outcomes and insurance status. Two reviewers independently selected studies. One investigator evaluated their quality according to predetermined criteria, and abstracted data about study design, patients' demographic and clinical characteristics, and outcome measures.
Measurements and main results: Of 3,798 potentially relevant studies, 23 met eligibility criteria and were included. Studies reported heterogeneous outcomes among heterogeneous samples of patients that precluded a quantitative synthesis. In general, compared with patients with private or Medicare insurance, patients with Medicaid or no insurance had poorer lung cancer outcomes, including higher incidence rates, later stage at diagnosis, and poorer survival. Overall, patients with Medicaid or no insurance were less likely to undergo curative procedures, but patients without insurance were more likely to receive guideline-concordant care.
Conclusions: Patients with Medicaid or no insurance consistently had worse outcomes than other patients with lung cancer. Some of the disparities may be secondary to residual confounding from smoking and other health behaviors, but available data suggest that patients with lung cancer without insurance do poorly because access to care is limited and/or they present with more advanced disease that is less amenable to treatment.
Similar articles
-
Disparities in Systemic Treatment Use in Advanced-stage Non-Small Cell Lung Cancer by Source of Health Insurance.Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1059-1066. doi: 10.1158/1055-9965.EPI-18-0823. Epub 2019 Mar 6. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 30842132
-
Access denied: The relationship between patient insurance status and access to high-volume hospitals.Cancer. 2021 Feb 15;127(4):577-585. doi: 10.1002/cncr.33237. Epub 2020 Oct 21. Cancer. 2021. PMID: 33084023
-
Discontinuous insurance coverage predicts prolonged hospital stay after pediatric adenotonsillectomy.J Surg Res. 2017 Oct;218:86-91. doi: 10.1016/j.jss.2017.05.078. Epub 2017 Jun 15. J Surg Res. 2017. PMID: 28985881
-
The impact of demographics, socioeconomics, and health care access on melanoma outcomes.J Am Acad Dermatol. 2021 Jun;84(6):1677-1683. doi: 10.1016/j.jaad.2020.07.125. Epub 2020 Aug 9. J Am Acad Dermatol. 2021. PMID: 32783908 Review.
-
Trends in private insurance, Medicaid/State Children's Health Insurance Program, and the health-care safety net: implications for asthma disparities.Chest. 2007 Nov;132(5 Suppl):818S-830S. doi: 10.1378/chest.07-1903. Chest. 2007. PMID: 17998346 Review.
Cited by
-
Effects of Medicaid managed care on early detection of cancer: Evidence from mandatory Medicaid managed care program in Pennsylvania.Health Serv Res. 2024 Oct;59(5):e14348. doi: 10.1111/1475-6773.14348. Epub 2024 Jul 3. Health Serv Res. 2024. PMID: 38958003
-
Medicaid Expansion Under the Affordable Care Act and Early Mortality Following Lung Cancer Surgery.JAMA Netw Open. 2024 Jan 2;7(1):e2351529. doi: 10.1001/jamanetworkopen.2023.51529. JAMA Netw Open. 2024. PMID: 38214932 Free PMC article.
-
Social Determinants of Health in Imaging-based Cancer Screening: A Case-based Primer with Strategies for Care Improvement.Radiographics. 2023 Nov;43(11):e230008. doi: 10.1148/rg.230008. Radiographics. 2023. PMID: 37824411 Free PMC article.
-
Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non-small cell lung cancer.J Thorac Cardiovasc Surg. 2024 Apr;167(4):1458-1466.e4. doi: 10.1016/j.jtcvs.2023.09.033. Epub 2023 Sep 21. J Thorac Cardiovasc Surg. 2024. PMID: 37741315
-
The evolution of payer management of oncology drugs in the United States between 2017 and 2022.J Manag Care Spec Pharm. 2023 Oct;29(10):1138-1149. doi: 10.18553/jmcp.2023.23045. Epub 2023 Sep 11. J Manag Care Spec Pharm. 2023. PMID: 37695273 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous